Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Di Mario, Simona ^a   Basevi, Vittorio ^a   Lopalco, Pier Luigi ^b   Balduzzi, Sara ^c   D'Amico, Roberto ^c   Magrini, Nicola ^d  

^a Public Health Service   (Italy)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d Regional Agency for Health and Social Care   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER PREVENTION; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CYTOLOGY; DRUG EFFICACY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INFECTION PREVENTION; META ANALYSIS (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SEXUALITY; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; VACCINATION; ADULT; ALPHAPAPILLOMAVIRUS; CANCER STAGING; CLASSIFICATION; COMPLICATION; FEMALE; HEALTH; IMMUNOLOGY; META ANALYSIS; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADULT; ALPHAPAPILLOMAVIRUS; CLINICAL TRIALS AS TOPIC; FEMALE; GLOBAL HEALTH; HUMANS; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84941087343     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/435141     Document Type: Review

References (78)

1. G. Clifford, S. Franceschi, M. Diaz, N. M͡noz, and L. L. Villa, "Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases, " Vaccine, vol. 24, supplement 3, pp. S26-S34, 2006
2. A. Sargent, A. Bailey, M. Almonte et al., "Prevalence of typespecific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial, " British Journal of Cancer, vol. 98, no. 10, pp. 1704-1709, 2008
3. R. Sankaranarayanan and J. Ferlay, "Worldwide burden of gynaecological cancer: the size of the problem, " Best Practice and Research: Clinical Obstetrics and Gynaecology, vol. 20, no. 2, pp. 207-225, 2006
4. M. Schiffman and P. E. Castle, "The promise of global cervicalcancer prevention, " The New England Journal of Medicine, vol. 353, no. 20, pp. 2101-2104, 2005
5. A.-B. Moscicki, N. Hills, S. Shiboski et al., "Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females, " The Journal of the American Medical Association, vol. 285, no. 23, pp. 2995-3002, 2001
6. K. Vinodhini, S. Shanmughapriya, B. C. Das, and K. Natarajaseenivasan, "Prevalence and risk factors of HPV infection among women from various provinces of the world, " Archives of Gynecology and Obstetrics, vol. 285, no. 3, pp. 771-777, 2012
7. L. Koutsky, "Epidemiology of genital human papillomavirus infection, " The American Journal ofMedicine, vol. 102, no. 5, pp. 3-8, 1997
8. I. H. Frazer, J. T. Cox, E. J. Mayeaux Jr. et al., "Advances in prevention of cervical cancer and other human papillomavirusrelated diseases, " Pediatric Infectious Disease Journal, vol. 25, no. 2, pp. S65-S81, 2006
9. G. Ronco, P. Giorgi-Rossi, F. Carozzi et al., "New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial, " The Lancet Oncology, vol. 11, no. 3, pp. 249-257, 2010
10. P. Oakeshott, A. Aghaizu, F. Reid et al., "Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study, " British Medical Journal, vol. 344, Article ID e4168, 2012
11. D. M. Harper, E. L. Franco, C. Wheeler et al., "Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial, " The Lancet, vol. 364, no. 9447, pp. 1757-1765, 2004
12. D. M. Harper, E. L. Franco, C. M. Wheeler et al., "Sustained efficacy up to 4?5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial, " The Lancet, vol. 367, no. 9518, pp. 1247-1255, 2006
13. J. Paavonen, D. Jenkins, F. X. Bosch et al., "Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial, " The Lancet, vol. 369, no. 9580, pp. 2161-2170, 2007
14. L. L. Villa, R. L. R. Costa, C. A. Petta et al., "Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 viruslike particle vaccine in young women: a randomised doubleblind placebo-controlled multicentre phase II efficacy trial, " Lancet Oncology, vol. 6, no. 5, pp. 271-278, 2005
15. L. L. Villa, R. L. R. Costa, C. A. Petta et al., "High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up, " British Journal of Cancer, vol. 95, no. 11, pp. 1459-1466, 2006
16. S. M. Garland, M. Hernandez-Avila, C. M. Wheeler et al., "Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases, "The New England Journal ofMedicine, vol. 356, no. 19, pp. 1928-1943, 2007
17. FUTURE II StudyGroup, "Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions, " The New England Journal of Medicine, vol. 356, pp. 1915-1927, 2007
18. FDA, Approval Letter-Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant, 2006, http://www .fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm111283.htm
19. AAVV, Scientific Discussion. Document for Registration of Gardasil to EMEA, 2006, http://www.ema.europa.eu/docs/en GB/document library/EPAR-Scientific Discussion/human/000703/WC500021140.pdf
20. AAVV, Scientific discussion, document for registration of Cervarix to EMEA, 2007, http://www.ema.europa.eu/docs/en GB/document library/EPAR-Scientific Discussion/human/000721/WC500024636.pdf
21. FDA, Clinical Review of Biologics License Application forHuman Papillomavirus 16, 18 L1 Virus Like Particle Vaccine, AS04 Adjuvant-Adsorbed (Cervarix), Food and Drug Administration, 2009, http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM237976.pdf
22. L. A. King, D. Levy-Bruhl, D. O'Flanagan et al., "VENICE Country Specific Gate Keepers and Contact Points. Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: results of the VENICE 2007 survey, " Euro Surveillance, vol. 13, no. 33, p. 18954, 2008
23. European Centre for Disease Prevention and Control, HPV Vaccination in EU Countries: Review of New Evidence, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden, 2014, http://ecdc.europa.eu/en/activities/sciadvice/layouts/forms/Review DispForm.aspx?List=a3216f4cf040-4f51-9f77-A96046dbfd72&ID=758
24. L. E. Markowitz, E. F. Dunne, M. Saraiya et al., "Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP), " Morbidity and Mortality Weekly Report, vol. 63, pp. 1-30, 2014
25. The NHS Choices, Vaccination. Cervical Cancer Vaccine, The NHS Choices, London, UK, 2014, http://www.nhs.uk/Conditions/vaccinations/Pages/hpv-human-papillomavirus-vaccine .aspx
26. N. M͡noz, S. K. Kjaer, K. Sigurdsson et al., "Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-Associated genital diseases in young women, " Journal of the National Cancer Institute, vol. 102, no. 5, pp. 325-339, 2010
27. M. Lehtinen, J. Paavonen, C. M. Wheeler et al., "HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-Adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial, " The Lancet Oncology, vol. 13, no. 1, pp. 89-99, 2012
28. The GlaxoSmithKline Vaccine HPV-007 Study Group, "Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-Adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years, " The Lancet, vol. 374, no. 9706, pp. 1975-1985, 2009
29. R. Konno, S. Tamura, K. Dobbelaere, and H. Yoshikawa, "Efficacy of human papillomavirus type 16/18 AS04-Adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial, " International Journal of Gynecological Cancer, vol. 20, no. 5, pp. 847-855, 2010
30. K. A. Ault and Future II Study Group, "Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials, "TheLancet, vol. 369, no.9576, pp. 1861-1868, 2007
31. G. Perez, P. E. Lazcano, A. M. Hernandez et al., "Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women, " International Journal of Cancer, vol. 122, no. 6, pp. 1311-1318, 2008
32. E. H. Tay, S. Garland, G. Tang et al., "Clinical trial experience with prophylacticHPV6/11/16/18VLP vaccine in youngwomen from the Asia-Pacific region, " International Journal of Gynecology and Obstetrics, vol. 102, no. 3, pp. 275-283, 2008
33. S. Majewski, F. Bosch, J. Dillner et al., "The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24, " Journal of the European Academy of Dermatology and Venereology, vol. 23, pp. 1147-1155, 2009
34. E. Barr, C. K. Gause, O. M. Bautista et al., "Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women, " American Journal of Obstetrics & Gynecology, vol. 198, no. 3, pp. 261.e1-261.e11, 2008
35. N. de Carvalho, J. Teixeira, C. M. Roteli-Martins et al., "Sustained efficacy and immunogenicity of the HPV-16/18 AS04-Adjuvanted vaccine up to 7.3 years in young adult women, " Vaccine, vol. 28, no. 38, pp. 6247-6255, 2010
36. B. Romanowski, "Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines, " Human Vaccines, vol. 7, no. 2, pp. 161-169, 2011
37. M. H. Einstein, M. Baron, M. J. Levin et al., "Comparison of the immunogenicity and safety ofCervarix andGardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years, " Human Vaccines, vol. 5, no. 10, pp. 705-719, 2009
38. M. H. Einstein, M. Baron, M. J. Levin et al., "Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years, " Human Vaccines, vol. 7, no. 12, pp. 1343-1358, 2011
39. L. Barzon, L. Squarzon, S. Masiero et al., "Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes, " Vaccine, vol. 32, no. 41, pp. 5357-5362, 2014
40. J. T. Schiller andD. R. Lowy, "Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials, " Journal of Infectious Diseases, vol. 200, no. 2, pp. 166-171, 2009
41. L. Rambout, L. Hopkins, B. Hutton, andD. Fergusson, "Prophylactic vaccination against human papillomavirus infection and disease inwomen: a systematic reviewof randomized controlled trials, " CanadianMedical Association Journal, vol. 177, no. 5, pp. 469-479, 2007
42. E. A. Joura, S. K. Kjaer, C. M. Wheeler et al., "HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine, " Vaccine, vol. 26, no. 52, pp. 6844-6851, 2008
43. B. Lu, A. Kumar, X. Castellsague, and A. R. Giuliano, "Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & metaanalysis, " BMC Infectious Diseases, vol. 11, article 13, 2011
44. L. Rey-Ares, A. Ciapponi, and A. Pichon-Riviere, "Efficacy and safety of human papilloma virus vaccine in cervical cancer prevention: systematic review and meta-Analysis, " Archivos Argentinos de Pediatria, vol. 110, no. 6, pp. 483-489, 2012
45. G. Traversa, L. Sagliocca, A. Liberati, andN. Martini, "The need to promote independent research on drugs, " Annals ofOncology, vol. 21, no. 11, p. 2295, 2010
46. D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and PRISMA Group, "Preferred reporting items for systematic reviews and meta-Analyses: the PRISMAstatement, " BritishMedical Journal, vol. 339, no. 7716, pp. 332-336, 2009
47. J. P. T. Higgins and S. Green, Eds., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, The Cochrane Collaboration, 2014, http://handbook.cochrane.org/
48. M. Greenwood and G. U. Yule, "The statistics of anti-typhoid and anti-cholera inoculations, " Proceedings of the Royal Society of Medicine, vol. 8, pp. 113-194, 1915
49. A. Orozco-Col?n, A. Carrillo-Garc?a, A. Mendez-Tenorio et al., "Geographical variation in human papillomavirus prevalence in Mexican women with normal cytology, " International Journal of Infectious Diseases, vol. 14, no. 12, pp. e1082-e1087, 2010
50. J. del Amo, C. Gonzalez, J. Belda et al., "Prevalence and risk factors of high-risk human papillomavirus in female sex workers in Spain: differences by geographical origin, " Journal of Women's Health (Larchmt), vol. 18, no. 12, pp. 2057-2064, 2009
51. N. M͡noz, F. X. Bosch, X. Castellsague et al., "Against which human papillomavirus types shall we vaccinate and screen? The international perspective, " International Journal of Cancer, vol. 111, no. 2, pp. 278-285, 2004
52. ClinicalTrails.Gov, Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults, ClinicalTrails.Gov, 2011, http://clinicaltrials.gov/ct2/show/NCT00120848?term=NCT00120848&rank=1
53. ClinicalTrails.Gov, Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18, ClinicalTrails .Gov, 2014, http://clinicaltrials.gov/ct2/show/NCT00122681 ?term=NCT00122681&rank=1
54. ClinicalTrails.Gov, Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil), ClinicalTrails.Gov, 2014, http://clinicaltrials.gov/ct2/show/NCT00092521?term=NCT00092521&rank=1
55. ClinicalTrails.Gov, Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015), ClinicalTrails.Gov, 2014, http://clinicaltrials.gov/ct2/show/NCT00092534?term=NCT00092534 &rank=1
56. ClinicalTrails.Gov, Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine, ClinicalTrails.Gov, 2011, http://clinicaltrials.gov/ct2/show/NCT00316693?term=nct00316693&rank=1
57. M. Stanley, "ProphylacticHPV vaccines: prospects for eliminating ano-genital cancer, " British Journal of Cancer, vol. 96, no. 9, pp. 1320-1323, 2007
58. K. A. Alexander and A. R. Giuliano, "HPV-beyond cervical cancer (online resource center), " The American Journal of Medicine, vol. 125, no. 7, article S1, 2012
59. F. X. Bosch, "Human papillomavirus: science and technologies for the elimination of cervical cancer, " Expert Opinion on Pharmacotherapy, vol. 12, no. 14, pp. 2189-2204, 2011
60. C. J. Haug, "Human papillomavirus vaccination-reasons for caution, " The New England Journal of Medicine, vol. 359, no. 8, pp. 861-862, 2008
61. M. Porta, B. Gonzalez, S.Marquez, and L. Artazcoz, "Doubts on the appropriateness of universal human papillomavirus vaccination: is evidence on public health benefits already available?" Journal of Epidemiology and Community Health, vol. 62, article 667, 2008
62. S. DiMario, V. Basevi, S. Borsari, S. Balduzzi, and N. Magrini, "Overall efficacy of HPV-16/18 AS04-Adjuvanted vaccine, " The Lancet Oncology, vol. 13, no. 2, p. e50, 2012
63. P. E. Gravitt, "The known unknowns of HPV natural history, " Journal of Clinical Investigation, vol. 121, no. 12, pp. 4593-4599, 2011
64. I. Mattheij, A.M. Pollock, and P. Brhlikova, "Do cervical cancer data justify HPV vaccination in India? Epidemiological data sources and comprehensiveness, " Journal of the Royal Society of Medicine, vol. 105, no. 6, pp. 250-262, 2012
65. J. C. Polzer and S. M. Knabe, "From desire to disease: Human Papillomavirus (HPV) and themedicalization of nascent female sexuality, " Journal of Sex Research, vol. 49, no. 4, pp. 344-352, 2012
66. M. Safaeian, A. Ghosh, C. Porras et al., "Direct comparison of HPV16 serological assays used to define HPV-nä?ve women in HPV vaccine trials, " Cancer Epidemiology Biomarkers and Prevention, vol. 21, no. 9, pp. 1547-1554, 2012
67. C. M. Roteli-Martins, P. Naud, P. de Borba et al., "Sustained immunogenicity and efficacy of the HPV-16/18 AS04-Adjuvanted vaccine: up to 8.4 years of follow-up, " Human vaccines & immunotherapeutics, vol. 8, no. 3, pp. 390-397, 2012
68. M. Lehtinen, D. Apter, G. Dubin et al., "Enrolment of 22, 000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing, " International Journal of STD and AIDS, vol. 17, no. 8, pp. 517-521, 2006
69. M. Jit, R. Chapman, O. Hughes, and Y. H. Choi, "Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model, " British Medical Journal, vol. 343, no. 7825, Article ID d5775, 2011
70. L. Garattini, K. van de Vooren, and N. Freemantle, "Tendering and value-based pricing: lessons from Italy on human papilloma virus vaccines, " Journal of the Royal Society ofMedicine, vol. 107, no. 1, pp. 4-5, 2014
71. B. Liu, B. Donovan, J. M. L. Brotherton, M. Saville, and J. M. Kaldor, "Genital warts and chlamydia in Australian women: comparison of national population-based surveys in 2001 and 2011, " Sexually Transmitted Infections, vol. 90, pp. 532-537, 2014
72. C. K. Fairley, J. S. Hocking, L. C. Gurrin, M. Y. Chen, B. Donovan, and C. S. Bradshaw, "Rapid decline in presentations of genitalwarts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women, " Sexually Transmitted Infections, vol. 85, no. 7, pp. 499-502, 2009
73. A. Szarewski, S. R. Skinner, S. M. Garland et al., "Efficacy of the HPV-16/18 AS04-Adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation, " The Journal of Infectious Diseases, vol. 208, no. 9, pp. 1391-1396, 2013
74. Z. Kmietowicz, "UK will use Gardasil in its HPV vaccination programme from next September, " The British Medical Journal, vol. 343, Article ID d7694, 2011
75. B. Serrano, L. Alemany, S. Tous et al., "Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease, " Infectious Agents and Cancer, vol. 7, no. 1, article 38, 2012
76. E. A. Joura, A. R. Giuliano, O. E. Iversen et al., "Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women, " The New England Journal of Medicine, vol. 372, pp. 711-723, 2015
77. The PLOS Medicine Editors, "Getting more generous with the truth: clinical trial reporting in 2013 and beyond, " PLOS Medicine, vol. 10, no. 1, Article IDe1001379, 2013
78. F. Godlee, "Clinical trial data for all drugs in current use, " British Medical Journal, vol. 345, no. 7881, Article IDe7304, 2012.